Skip to main content

Advertisement

SpringerLink
Log in

Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Advances in chemotherapy for breast cancer (BC) have prolonged overall survival, especially for patients with human epidermal growth factor receptor-2 (HER2) positive cancer. We evaluated the effectiveness and limitations of stereotactic radiosurgery (SRS) for brain metastases (BM) from BC in conjunction with molecular targeting chemotherapy. Outcomes were retrospectively reviewed in 80 consecutive patients who underwent gamma knife SRS for BM from BC between January 2009 and February 2012. The overall survival (OS), neurological death-free survival (NS) and local tumor control endpoints were calculated, and prognostic factors were investigated using proportional hazards models. In 40 patients with HER2-overexpression, treatment results were compared between two sub-groups: lapatinib-based therapy (24 patients) versus non-lapatinib-based therapy (16 patients). The rates of 1- and 2-year OS after SRS were 50 and 26 %, respectively. The median survival time (MST) was 11.4 months. HER2-overexpression (P < 0.001), recursive partitioning analysis class (P = 0.018) and total planning target volume on initial SRS (P = 0.004) were associated with OS. The MSTs in HER2-positive and –negative patients were 16.6 and 7.1 months, respectively (P = 0.001). The rates of 1- and 2-year NS were 90 and 78 %, respectively. The rates of 1- and 2-year local tumor control were 84 and 70 %, respectively. Factors associated with local tumor control included lesion volume (P < 0.001) and peripheral dose (P = 0.003). In sub-analysis of patients with HER2-overexpression, lapatinib-based chemotherapy was also associated with better local tumor control (P = 0.002). The 1-year local tumor control rate of the lapatinib group was significantly better than that of the non-lapatinib group (86 vs. 69 %, P < 0.001). SRS is a safe and effective management option for selected patients with BM from BC. Patients with HER2-overexpressing tumors were found to be a distinct subgroup for which a longer survival time can be expected. Synergistic anti-tumor effects of lapatinib on BM in conjunction with SRS were suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617

    Article  Google Scholar 

  2. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977

    Article  Google Scholar 

  3. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13:739–750

    Article  Google Scholar 

  4. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O’Brien ME, Smith IE (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196–201

    Article  CAS  Google Scholar 

  5. Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, Gachet J, Labib A, Mouret-Fourme E (2011) Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 11:395

    Article  Google Scholar 

  6. Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH (2002) Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 54:810–817

    Article  Google Scholar 

  7. Karam I, Nichol A, Woods R, Tyldesley S (2011) Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era. Radiat Oncol 6:181

    Article  Google Scholar 

  8. Kondziolka D, Kano H, Harrison GL, Yang HC, Liew DN, Niranjan A, Brufsky AM, Flickinger JC, Lunsford LD (2011) Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. J Neurosurg 114:792–800

    Article  Google Scholar 

  9. Muacevic A, Kreth FW, Tonn JC, Wowra B (2004) Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer 100:1705–1711

    Article  Google Scholar 

  10. Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH (2009) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 20:56–62

    Article  CAS  Google Scholar 

  11. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459

    Article  CAS  Google Scholar 

  12. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82(5):2111–2117

    Article  Google Scholar 

  13. Yomo S (2012) Hayashi M. A prospective pilot study of two-session gamma knife surgery for large metastatic brain tumors. J Neurooncol, Nicholson C

    Google Scholar 

  14. Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger JC, Lunsford LD (2010) T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery 66:486–491 discussion 491–482

    Article  Google Scholar 

  15. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S (2009) Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 30:367–372

    Article  CAS  Google Scholar 

  16. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K (2008) Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694–699

    Article  Google Scholar 

  17. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346

    Article  CAS  Google Scholar 

  18. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154

    Article  Google Scholar 

  19. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509

    Article  Google Scholar 

  20. Yomo S, Hayashi M (2012) Fatal tumoral hemorrhage after stereotactic radiosurgery for metastatic brain tumors: report of three cases and review of literature. Acta Neurochir (Wien) 154(9):1685–1690

    Article  Google Scholar 

  21. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648–1655

    Article  CAS  Google Scholar 

  22. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

    Article  CAS  Google Scholar 

  23. Kased N, Binder DK, McDermott MW, Nakamura JL, Huang K, Berger MS, Wara WM, Sneed PK (2009) Gamma knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys 75:1132–1140

    Article  Google Scholar 

  24. Serizawa T, Saeki N, Higuchi Y, Ono J, Iuchi T, Nagano O, Yamaura A (2005) Gamma knife surgery for brain metastases: indications for and limitations of a local treatment protocol. Acta Neurochir (Wien) 147:721–726 discussion 726

    Article  CAS  Google Scholar 

  25. Grandhi R, Kondziolka D, Panczykowski D, Monaco EA III, Kano H, Niranjan A, Flickinger JC, Lunsford LD (2012) Stereotactic radiosurgery using the Leksell gamma knife perfexion unit in the management of patients with 10 or more brain metastases. J Neurosurg 117(2):237–245

    Article  Google Scholar 

  26. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD (2006) Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64:898–903

    Article  Google Scholar 

  27. Monaco EA 3rd, Faraji AH, Berkowitz O, Parry PV, Hadelsberg U, Kano H, Niranjan A, Kondziolka D, Lunsford LD (2012) Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 119(1):226–232

    Article  Google Scholar 

  28. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044

    Article  Google Scholar 

  29. Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 63:37–46

    Article  Google Scholar 

  30. Yang CC, Ting J, Wu X, Markoe A (1998) Dose volume histogram analysis of the gamma knife radiosurgery treating twenty-five metastatic intracranial tumors. Stereotact Funct Neurosurg 70(Suppl 1):41–49

    Article  Google Scholar 

  31. Yamamoto M, Ide M, Nishio S, Urakawa Y (2002) Gamma knife radiosurgery for numerous brain metastases: is this a safe treatment? Int J Radiat Oncol Biol Phys 53:1279–1283

    Article  Google Scholar 

  32. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491

    Article  CAS  Google Scholar 

  33. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630–1639

    Article  CAS  Google Scholar 

  34. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092–1103

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful to Bierta Barfod, M.D., M.P.H. for her help with the preparation of this manuscript.

Conflict of interest

The authors have no personal, financial or institutional interests in any of the materials or devices described in this article.

Author information

Authors and Affiliations

  1. Saitama Gamma Knife Center, San-ai Hospital, 4-35-17, Tajima, Sakura-ku, Saitama, 338-0837, Japan

    Shoji Yomo, Motohiro Hayashi & Narisumi Cho

Authors
  1. Shoji Yomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Motohiro Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Narisumi Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shoji Yomo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yomo, S., Hayashi, M. & Cho, N. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer. J Neurooncol 112, 199–207 (2013). https://doi.org/10.1007/s11060-013-1046-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-013-1046-1

Keywords

Search

Navigation